Statement of Principles concerning hypothyroidism (Reasonable Hypothesis) (No. 3 of 2022)

The instrument revolves around a small number of linked legal‑medical concepts: the statutory provenance of SoPs, the operational definition of hypothyroidism, the "reasonable hypothesis" evidentiary threshold, enumerated causal or precipitating factors with precise temporal windows, the distinction between onset and clinical worsening, and the relationship to "relevant service".

1. Statutory provenance. The instrument is made under s 196B(2) of the VEA (s 3). It therefore sits within the statutory architecture that authorises the Repatriation Medical Authority to issue SoPs relevant to the adjudication of veteran entitlements. The instrument itself repeats that authority (s 3).

2. Condition definition. Hypothyroidism is defined as a functional disorder producing clinical symptoms or requiring treatment (s 7(2)(a)). It expressly includes primary, central and peripheral forms (s 7(2)(b)(i)-(iii)) and excludes specific entities such as congenital hypothyroidism, congenital iodine‑deficiency syndrome, Hashimoto thyroiditis, sick euthyroid syndrome, subclinical hypothyroidism and transient hypothyroidism during recovery from non‑thyroidal illness (s 7(2)(c)). Notes in s 7 and the Schedule add clinical test patterns and clinical presentation (notes 1-5 and Schedule definitions).

3. Reasonable hypothesis and factors. Section 9 contains the central operational test: at least one of the listed factors must exist as a minimum before a reasonable hypothesis can be raised that links the hypothyroidism (or death from it) with the circumstances of relevant service. The factors are precise and time‑bound. They cover exposures (iodine deficiency/excess, iodine contrast), medications (a "specified list of drugs", minocycline, drugs with ≥10 mg iodine, amiodarone, drugs that increase thyroid hormone requirement), physiological states (pregnancy/postpartum), prior disorders of or iatrogenic injury to the thyroid (surgery, radioactive iodine, therapeutic radiation in‑field), comorbid diseases (specified list of diseases, hepatitis C, chronic kidney disease), obesity for a stated period (BMI ≥30 for at least 5 years), psychiatric diagnosis (PTSD), and inability to obtain appropriate clinical management. There are parallel items for clinical worsening and for myxoedema coma (ss 9(1)-(44)).

4. Onset versus worsening. The instrument separately addresses clinical onset (ss 9(1)-(21)) and clinical worsening (ss 9(22)-(44)). For worsening, many of the same exposures apply but with added specific items such as drugs that increase the requirement for replacement therapy (s 9(29)) and inability to obtain appropriate clinical management (s 9(44)).

5. Relationship to service. The factors must be tied to the person's relevant service (s 10(1)). The instrument narrows the use of the latter group (ss 9(22)-(44)) to claims of material contribution or aggravation where the hypothyroidism pre‑existed or was contracted before/during service but "did not arise out of" service (s 10(2)). This creates an explicit legal boundary between establishing causation arising out of service (onset) and establishing material contribution or aggravation of a pre‑existing condition by service.

6. Inter‑SoP interaction. Section 11 states that if a factor refers to an injury or disease covered by a different SoP determined under s 196B(2) of the VEA, the factors in that other SoP apply as in force from time to time. The instrument therefore expressly contemplates cross‑applicability and defers to specialised SoPs for overlapping disease states (for example Hashimoto thyroiditis; note in s 7(2) and Schedule entries).

7. Numeric and diagnostic thresholds. The Schedule provides quantitative thresholds used in the SoP,e.g. iodine deficiency/excess cutoffs expressed as daily intakes (micrograms per day) or urinary iodine concentrations (micrograms per litre), BMI calculation and threshold for obesity, chronic kidney disease criteria (GFR <60 mL/min/1.73 m2 for ≥3 months, albuminuria ≥3 mg/mmol for ≥3 months, renal biopsy/imaging/other markers, prior kidney transplant), and albuminuria definition (Schedule 1).

These concepts structure how a decision‑maker will treat medical and exposure evidence for claims falling within ss 120A VEA or 338 MRCA: the SoP provides binary, specified triggers (if at least one factor is satisfied within the timescale and related to relevant service) that establish a "reasonable hypothesis" for a link between hypothyroidism and service.

The instrument affects a defined population and several decision‑making actors by changing the factual and evidentiary scaffolding used in claims under the VEA and MRCA. The instrument explicitly applies to "a claim to which section 120A of the VEA or section 338 of the MRCA applies" (s 5). The Schedule defines "relevant service" to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1). Therefore, the affected persons are veterans or former members of the Forces whose claims for hypothyroidism, worsening of hypothyroidism, or death from hypothyroidism are assessed under the statutory provisions cross‑referenced in s 5.

Who decides: the instrument is determined by the Repatriation Medical Authority under s 196B(2) (s 3). The SoP is therefore an RMA product that will be used in adjudication of covered claims under the VEA/MRCA framework. The instrument itself does not name the statutory decision‑maker for individual claims, but by its application clause it sits inside the pathways established by s 120A VEA and s 338 MRCA , the statutory claims frameworks that govern benefits for service‑related injury and disease.

Who documents and produces evidence: claimants (veterans and service personnel) and their advisers will be required to assemble medical and exposure evidence matching the factors and quantitative thresholds in the SoP. Concretely this will include medical records and test results (thyroid function tests, urinary iodine concentration, BMI records, GFR and albuminuria records), medication dispensing information (names, doses, durations), radiology and surgical reports (contrast administration, neck surgery, fields and doses of therapeutic radiation), infectious disease diagnoses (e.g. hepatitis C), psychiatric diagnoses (PTSD), oncology records for tumours expressing type 3 deiodinase or thyroid malignancy, and documentation of pregnancy/postpartum status relative to onset/worsening dates.

Who bears costs and burdens: the immediate compliance costs fall on claimants and their advisers to procure and present the specified evidence within the relevant time windows. Indirect administrative costs and decision time will fall on the agencies administering claims under the VEA/MRCA who must assess whether at least one of the listed factors exists and whether it is related to the person's relevant service (s 10(1)). Repeal of the prior 2013 SoP (s 4) means dossiers might need updating to reflect any differences between the old and new lists or threshold definitions; that imposes transitional evidentiary work on both claimants and decision‑makers.

Who is not covered: claims outside the stated statutory hooks (s 5) are not covered by this instrument. The instrument also excludes certain thyroid conditions from the definition of hypothyroidism for its purposes , e.g. congenital hypothyroidism, Hashimoto thyroiditis (s 7(2)(c)(i) & (iii)) , and notes that if hypothyroidism is a clinical manifestation of Hashimoto thyroiditis the separate Hashimoto SoP applies. Additionally, subsections 9(22)-(44) apply only in the context of material contribution or aggravation where the hypothyroidism pre‑existed or was contracted before/during service but did not arise out of service (s 10(2)), narrowing the class of claims to which those factors can meaningfully attach.

In short, the instrument affects veterans and members whose claims for hypothyroidism-related entitlements are adjudicated under the VEA/MRCA clauses specified in s 5, the medical practitioners and record‑holders who supply the requisite evidence, and the administrative decision‑makers who must apply a set of enumerated, time‑bounded factors and linked definitions to those claims.

The instrument is not a statute of general civil duties; it is a medical‑legal standard intended to be used in adjudicating claims under the VEA and MRCA. Its operative legal effects create duties and evidentiary expectations for parties participating in those claims processes rather than criminal or regulatory duties in the abstract. The following key duties, rights and procedures are embedded in or implied by the instrument's provisions.

1. Duty to apply the SoP in relevant claims contexts. The instrument is expressly made under s 196B(2) of the VEA (s 3) and applies to claims to which s 120A VEA or s 338 MRCA applies (s 5). Administrative decision‑makers responsible for those statutory provisions will be required to take the SoP into account as part of their assessment of whether a "reasonable hypothesis" exists. The SoP supplies the factors that, if at least one exists and is related to relevant service, constitute the minimum for raising a reasonable hypothesis (s 9).

2. Duty to prove temporal and factual elements. The claimant bears the practical obligation to adduce evidence matching the factor's specifics and time windows. Each factor in s 9 is expressed with a temporal element , e.g. within six months before clinical onset (ss 9(1)-(4)), specified durations of drug exposure (s 9(5)-(7)), or clinical states "at the time of" clinical onset or worsening (multiple subsections). Where the factor is a quantitative measurement (iodine deficiency/excess, BMI, albuminuria, GFR), the Schedule supplies the numeric thresholds that must be met (Schedule 1). Parties therefore must provide contemporaneous or retrospective clinical records that meet those thresholds.

3. Right to have a reasonable hypothesis considered. The SoP sets an evidentiary floor: at least one of the listed factors must exist before it can be said that a reasonable hypothesis has been raised connecting hypothyroidism or death from hypothyroidism with service (s 9). If a claimant provides evidence satisfying one of the factors, they have the right to have their claim assessed on that basis within the statutory process under the referenced sections of the VEA and MRCA.

4. Duty to relate the factor to relevant service. Section 10(1) requires that the existence in the person of any factor in s 9 "must be related to the relevant service rendered by the person." That is an additional causal link beyond merely showing the factor existed. For factors in ss 9(22)-(44) (those dealing with clinical worsening and other items), s 10(2) further confines their applicability to propositions of material contribution or aggravation where hypothyroidism pre‑existed or was contracted before/during, but did not arise out of, relevant service. Practically, this requires evidence not just of exposure but of a service connection , for example timelines, records of exposure during service, or medical evidence linking a service event to an exposure.

5. Right to cross‑reference other SoPs. Section 11 provides that where a factor in this SoP refers to an injury or disease covered by another SoP, the factors in that other SoP apply "in accordance with the terms of that Statement of Principles as in force from time to time." This gives claimants a route to rely on specialised SoPs (for example Hashimoto thyroiditis) when the relevant factor points to an overlap. The right is limited to the terms of those other SoPs and to their current form.

6. Duty to observe exclusions. The instrument clearly excludes certain conditions from its definition of hypothyroidism (s 7(2)(c)) , e.g. congenital hypothyroidism, Hashimoto thyroiditis, subclinical hypothyroidism. If a claimant’s condition is one of the excluded categories, the SoP does not operate to raise a reasonable hypothesis for hypothyroidism under this instrument; instead, if the condition is the subject of another SoP, that SoP must be consulted (s 11 and note to s 7(2)(c)(iii)).

7. Duty to prove onset vs aggravation distinctions. Because the SoP distinguishes between clinical onset and clinical worsening, claimants and decision‑makers must be precise about the date(s) of onset, dates of worsening, and temporal relationship of any listed factors. Several factors are applicable only in the specific contexts of onset, worsening, or myxoedema coma (e.g. s 9(21) and s 9(43) for myxoedema coma).

8. Evidence‑gathering duties implied by numeric thresholds. The Schedule establishes numeric cutoffs for iodine deficiency/excess and other clinical measures. To make those measures usable in adjudication, claimants or medical professionals must produce appropriate laboratory tests (urinary iodine concentration, GFR, albuminuria), medication records establishing duration and dose, imaging or surgical reports, and other clinical documentation.

The instrument itself does not create criminal sanctions, civil fines or new statutory penalties. Its legal effect is to supply a medical‑legal standard that produces duties of proof, creates rights to have a particular standard applied to a claim under specified statutory sections, and generates procedural and evidentiary expectations for claimants, medical practitioners and the administrative decision‑makers handling VEA/MRCA claims.

The Statement of Principles instrument does not create standalone criminal or civil penalties within its text. It is a medical‑legal standard made under s 196B(2) of the VEA (s 3) to be applied in the context of claims under the VEA and MRCA (s 5). The instrument itself contains no provisions imposing fines, imprisonment, licensing sanctions, or direct enforcement mechanisms against individuals or organisations for non‑compliance with its terms.

Enforcement of the instrument’s effect occurs in the context of the statutory claims processes under the VEA and MRCA. The instrument establishes the factors that must exist to raise a reasonable hypothesis that hypothyroidism or death from hypothyroidism is related to relevant service (s 9). It follows that administrative decision‑makers tasked with applying the VEA/MRCA provisions referenced in s 5 will use this SoP as part of their adjudicative framework when deciding entitlement questions. The instrument therefore affects the outcome of administrative determinations: if the claimant cannot establish at least one of the factors in s 9, a reasonable hypothesis of service connection will not be established on the SoP’s terms.

Practical enforcement mechanisms are therefore procedural and administrative rather than criminal. They include:

• Adjudication of entitlements under the VEA/MRCA: decision‑makers will accept or reject the existence of the listed factors and the required relationship to relevant service. The instrument supplies the minimum triggers for a "reasonable hypothesis" but does not itself declare the ultimate claim outcome; the outcome will depend on the broader statutory rules and evidentiary regimes in ss 120A VEA and 338 MRCA (s 5).

• Repeal and replacement: s 4 repeals the prior SoP No. 29 of 2013. That repeal changes the operative standard for claims after the commencement date and thus can lead to different outcomes for pending or new claims, which is an administrative enforcement effect by substitution.

• Cross‑SoP application: s 11 requires that if any factor refers to an injury/disease covered by another SoP, the factors in that other SoP apply in accordance with its terms. This creates an administrative obligation on decision‑makers to cross‑check other SoPs and apply their factors.

The instrument contains various definitional thresholds and specific temporal requirements that, in practice, function as evidentiary hurdles. Failure to meet those hurdles means the reasonable hypothesis is not raised and the claimant may not obtain entitlements under the respective statutory provisions. However, the instrument does not specify sanctions for false statements, fraudulent evidence, or other misconduct; those issues would be governed by other statutes and administrative instruments outside the text of this SoP.

Finally, the instrument’s enforcement risk for claimants is essentially the risk of an adverse administrative outcome (rejection of the claim) where evidence does not meet the SoP’s factors or where relationship to relevant service cannot be shown. The instrument does not itself prescribe remedial pathways, appeals, or penalties; those mechanisms will exist within the VEA/MRCA frameworks and ordinary administrative review or merits review processes.

This instrument is explicitly situated within and interacts with the legislative frameworks of the VEA and the MRCA. Its interplay points are mostly internal to that statutory architecture and to other Repatriation Medical Authority Statements of Principles. The instrument itself identifies the following interactions.

1. Authority relationship with the VEA. The SoP is made under subsection 196B(2) of the VEA (s 3). That statutory provision authorises the Repatriation Medical Authority to determine SoPs; the instrument therefore derives its legal force from the VEA. The instrument applies to claims to which s 120A of the VEA applies (s 5). The exact legal effects of SoPs within the broader VEA claim process (how they interact with other evidentiary rules in the VEA) are not restated in the instrument; it simply records its statutory source and the particular claim hooks where it applies.

2. Interaction with the MRCA. The instrument also applies to claims to which s 338 of the Military Rehabilitation and Compensation Act 2004 applies (s 5) and defines MRCA in the Schedule (Schedule 1). By cross‑referencing MRCA s 338, the SoP is made available for use in the MRCA statutory scheme.

3. Repeal of prior SoP. Section 4 repeals the Statement of Principles concerning hypothyroidism No. 29 of 2013. That repeal changes the operative SoP used in claims made after commencement and therefore interacts with prior adjudications, pending claims, and any transitional rules under the VEA/MRCA framework. The instrument does not itself set transitional rules; it simply repeals the prior instrument.

4. Cross‑SoP referencing. Section 11 establishes an operational interaction with other SoPs: if a factor in this SoP refers to an injury or disease covered by another SoP made under s 196B(2), the factors in that other SoP apply according to its terms. The instrument therefore defers to specialised SoPs where diseases overlap. The note to s 7(2)(c)(iii) illustrates that interplay: clinical hypothyroidism produced by Hashimoto thyroiditis is to be treated under the SoP concerning Hashimoto thyroiditis.

5. Interaction with medical/diagnostic standards. The Schedule imports medical and laboratory thresholds (e.g. urinary iodine concentration cutoffs, daily iodine intake cutoffs, BMI calculation and threshold, chronic kidney disease criteria such as GFR and albuminuria durations). These are medical standards that must be met for the SoP’s factors to be satisfied. The SoP therefore interacts functionally with the clinical laboratory and diagnostic regime: decisions under the VEA/MRCA will need to consider these numerical results and clinical criteria as evidence.

6. Limited scope of statutory interaction. The instrument does not attempt to amend, supplant or restate the VEA or MRCA substantive entitlements; it operates as a focused evidentiary/medical standard for the limited question of whether a reasonable hypothesis connects hypothyroidism to relevant service where claims are brought under the specified statutory sections (s 5). It does not purport to create or extinguish rights outside those statutory claim pathways.

7. Administrative procedure and appeal frameworks. The instrument does not itself set appeal or review procedures. Therefore, its practical interaction with the broader law will be mediated by the procedural, merits review or judicial review mechanisms in the VEA and MRCA regimes for contesting claims decisions that have used this SoP.

8. Interaction with other statutory regimes (not specified). The instrument does not reference other Acts such as privacy, evidence, or professional regulation statutes, nor does it provide instructions on handling medical records or confidentiality. Any interaction with those regimes is left to the ordinary operation of law and administrative practice.

In sum, the instrument functions as a medical‑legal module inserted into the VEA/MRCA claim frameworks. It interacts directly by supplying the SoP to be applied in claims falling under s 120A VEA or s 338 MRCA, replacing the prior hypothyroidism SoP, and cross‑referencing other SoPs where diseases overlap. Its practical application requires engagement with medical diagnostic standards and the administrative procedures contained in the underlying statutes.

This instrument replaces an earlier Repatriation Medical Authority Statement of Principles concerning hypothyroidism. The relevant amendment history recorded in the instrument is as follows.

• New instrument: Statement of Principles concerning hypothyroidism (Reasonable Hypothesis) (No. 3 of 2022), determined by the Repatriation Medical Authority and dated 24 December 2021 (s 1 and the instrument heading). It commences on 31 January 2022 (s 2).

• Repeal of prior instrument: Section 4 expressly repeals "The Statement of Principles concerning hypothyroidism No. 29 of 2013 (Federal Register of Legislation No. F2013L00728) made under subsections 196B(2) and (8) of the VEA." The instrument does not include a saved or transitional provision; it simply states the prior instrument is repealed.

The instrument does not list any prior amendments to the 2013 instrument within its text. It also does not set out transitional arrangements, grandfathering provisions, or retroactivity rules. The only temporal direction is the commencement date (31 January 2022) and the repeal of the prior SoP (s 4). Practitioners should therefore note that, from commencement, this SoP is the operative RMA statement for hypothyroidism under the statutory hooks in s 5, and the prior SoP is no longer in force.

Because the instrument expressly contemplates cross‑application of other SoPs "as in force from time to time" (s 11), there is an implicit ongoing amendment dynamic: future amendments to other SoPs will affect how factors that overlap with those other injuries/diseases are applied. The instrument’s language thus ensures it will operate alongside other SoPs as they evolve.

The Schedule itself contains defined terms and numeric thresholds that constitute the technical content of the SoP. Any future amendment to those thresholds or to the specified lists of drugs, diseases or forms of thyroiditis will alter the operative content of the SoP. The instrument does not record a history of prior changes to the specified lists or to the Schedule definitions.

For administrative users and claimants, the practical consequences of this amendment history are: (a) replace reliance on the 2013 SoP with the 2022 instrument after 31 January 2022; (b) check whether factors that were previously sufficient under the 2013 instrument have changed in wording, temporal windows, numeric thresholds or lists (the instrument does not provide a redline comparison); and (c) where factors refer to other SoPs, verify the current terms of those other SoPs at the time of claim (s 11).

The instrument itself contains no litigation history and does not record any judicial or tribunal decisions interpreting its content. It is a stand‑alone RMA instrument; the text does not reference any cases, appeals, or determinations about prior SoPs. Consequently there is no litigation history recited in the primary text.

From the instrument’s content, however, one can identify several categories of potential interpretive and litigation risk that decision‑makers and claimants might litigate if disputes arise:

• Interpretation of temporal windows and documentary standards. Section 9 contains numerous time‑bounded factors (e.g. "within the 6 months before the clinical onset" at ss 9(1)-(4), "for at least 6 months within the 9 months before" for minocycline at s 9(5), "continuous period of at least 4 weeks within the 6 months" for drugs with ≥10 mg iodine at s 9(6), "continuous period of at least 2 weeks within the 1 year" for amiodarone at s 9(7)). Disputes may arise over how to count days, whether gaps break continuity, or what constitutes "within" a period. Courts and tribunals often resolve such temporal disputes in statutory contexts; here, the SoP furnishes potential points of contention.

• Quantitative measures and sample timing. The Schedule supplies numeric cutoffs for urinary iodine concentration and average daily iodine intake. Litigation could arise over the admissibility and timing of laboratory tests, the validity of retrospective estimates of daily intake, or whether a single urinary iodine measurement can establish a period of deficiency/excess (the Schedule sets time periods for intake (≥30 days continuous) and for urinary concentrations but does not prescribe sampling regimens).

• Relationship to relevant service. Section 10(1) requires that the existence of any factor "must be related to the relevant service rendered by the person." Proof of that relationship may be contentious where exposures occurred before, during, or after service, or where service records are incomplete. Section 10(2) further narrows the operation of ss 9(22)-(44) to material contribution/aggravation where hypothyroidism was pre‑existing or contracted before/during but "did not arise out of" the person's relevant service. That phrasing lends itself to disputes over the statutory tests for aggravation and material contribution under the VEA/MRCA frameworks.

• Overlap with other SoPs. Section 11 mandates that where a factor refers to a disease covered by another SoP, the other SoP's factors apply. Litigation could concern which SoP governs in overlapping presentations , for example, clinical hypothyroidism manifesting in the context of Hashimoto thyroiditis where the Hashimoto SoP applies. Parties may litigate which SoP’s criteria should be applied and how to treat overlapping factors.

• Clinical definitions and diagnostic uncertainties. The SoP excludes "subclinical hypothyroidism" and "sick euthyroid syndrome" (s 7(2)(c)(iv)-(v)). Disagreements about whether a claimant’s presentation is "subclinical" or clinical hypothyroidism, and whether biochemical and clinical evidence satisfies the SoP's definition, may generate disputes. The Schedule provides definitions but also leaves clinical judgement (e.g. "clinical symptoms and signs") to be assessed.

• Interpretation of "inability to obtain appropriate clinical management." Item 9(44) includes "inability to obtain appropriate clinical management for hypothyroidism" as a factor for worsening. That phrase is broad and may be litigated regarding its threshold and what evidence properly demonstrates such inability.

Because the instrument is new as of its commencement and the text lists no existing decisions, any litigation history will develop only as claimants and decision‑makers challenge or rely on the SoP in contested claims. Practitioners should therefore monitor Tribunal and court authorities for early decisions that interpret key provisions, particularly s 9 temporal tests, Schedule numeric thresholds, s 10 relationship tests, and s 11 interaction with other SoPs.

This instrument contains several drafting features and substantive details that create pitfalls for claimants, advisers and decision‑makers if overlooked. The following "gotchas" are drawn directly from the instrument’s text and Schedule.

1. Exclusions from the definition of hypothyroidism. The instrument excludes Hashimoto thyroiditis from its definition of hypothyroidism (s 7(2)(c)(iii)). The note to s 7(2) clarifies that if hypothyroidism is a clinical manifestation of Hashimoto thyroiditis, it is covered by the SoP concerning Hashimoto thyroiditis. Practically, if a claimant’s hypothyroidism is Hashimoto‑related, this SoP will not be the correct instrument; the claimant must consult the Hashimoto SoP, per s 11. Missing this cross‑reference will lead to applying the wrong factors.

2. Different factors for onset versus worsening. The instrument separates onset (ss 9(1)-(21)) and clinical worsening (ss 9(22)-(44)). Some factors repeat across both lists but the legal effect differs because s 10(2) restricts ss 9(22)-(44) to material contribution/aggravation where hypothyroidism pre‑existed or was contracted before/during, but did not arise out of, service. Claimants and advisers must be precise about whether they are alleging onset due to service or aggravation of a pre‑existing condition.

3. Temporal precision and continuity requirements. Several factors require specific continuous exposure durations within defined look‑back windows: e.g. minocycline "for at least 6 months within the 9 months before" onset (s 9(5)); drugs containing ≥10 mg iodine "for a continuous period of at least 4 weeks within the 6 months before" onset (s 9(6)); amiodarone "for a continuous period of at least 2 weeks within the 1 year before" onset (s 9(7)). Evidence must establish both duration and timing; fragmented records or gaps in dispensing can defeat these factors.

4. Quantitative thresholds require specific tests or records. Iodine deficiency/excess are defined numerically in the Schedule by either average intake or urinary iodine concentration. For example, iodine deficiency may be an average intake <150 µg/day (or <250 µg/day for pregnant/lactating women) for a continuous period of at least 30 days, or urinary iodine <100 µg/L (or <150 µg/L for pregnant women). Similarly, iodine excess uses >1,100 µg/day or urinary iodine >300 µg/L (with different pregnancy thresholds). Where claimants lack contemporaneous dietary records or urinary iodine measurements, establishing these numeric thresholds retrospectively will be difficult.

5. Drugs lists and examples matter. The Schedule includes a "specified list of drugs" (Schedule 1) that ranges from alemtuzumab to valproic acid. Some drugs are expressed as categories (e.g. "tyrosine kinase inhibitors"), and some example drugs are mentioned in notes (e.g. drugs that may increase replacement requirement include 5‑fluorouracil, antiretroviral drugs, clofibrate, raloxifene, tamoxifen). Practitioners must check the specified list closely; reliance on a drug that is not listed will fail the factor test even if clinically relevant.

6. "Being obese for at least 5 years" requires BMI history. The Schedule defines being obese as BMI ≥30 and supplies the BMI formula. For the obesity factor in s 9(19) and s 9(41), the claimant must show BMI ≥30 for at least 5 years before onset/worsening. Intermittent or sparse weight records may make this impossible to prove.

7. Myxoedema coma specifics. Certain factors apply only when hypothyroidism first presents as myxoedema coma (s 9(21)) or for its worsening (s 9(43)). Myxoedema coma has a specific clinical definition in the Schedule. Misclassification of severe hypothyroidism as myxoedema coma (or vice versa) can change which factors are relevant.

8. Relationship to relevant service is required for all factors. Section 10(1) requires that any factor in s 9 "must be related to the relevant service rendered by the person." Establishing relation to service is a separate evidentiary task beyond showing the factor existed. For ss 9(22)-(44), s 10(2) adds the constraint that the hypothyroidism must have been suffered or contracted before or during service and did not arise out of service , a nuanced legal constraint that can be missed.

9. "Inability to obtain appropriate clinical management" is a broad and potentially subjective factor. Item 9(44) allows inability to obtain appropriate care as a factor for worsening. What counts as "appropriate" management is not defined in the instrument; claimants must provide robust evidence about attempts to obtain care, service availability, records of referrals, correspondence and clinical consequences.

10. Cross‑SoP application may change required evidence. Where a factor points to another SoP (s 11), the other SoP's factors apply "as in force from time to time." This means a claimant who believes a factor refers to another disease must identify the current text of that SoP and meet its requirements; failure to do so can jeopardise a claim.

11. Repeal without transitional guidance. Section 4 repeals the 2013 SoP but the instrument does not set out transitional provisions or how pending claims are to be treated. Practitioners should verify whether administrative guidance or the underlying statutes provide transitional rules.

12. Excluded diagnoses and clinical overlap. The instrument excludes conditions such as "sick euthyroid syndrome" and "subclinical hypothyroidism" (s 7(2)(c)(iv)-(v)). Clinical presentations that border these exclusions require careful clinical documentation and expert synthesis to demonstrate that the claimant’s condition meets the SoP’s working definition of hypothyroidism.

13. Specified list of diseases includes systemic and infectious disorders. The Schedule's specified diseases include items such as sarcoidosis, systemic lupus erythematosus, tuberculosis and others. If a claimant has one of these conditions at the time of onset/worsening, it is a listed factor , but practitioners must supply contemporaneous evidence linking the disease to the hypothyroid presentation.

Failure to attend to these "gotchas" can result in misapplication of the SoP, missed opportunities to raise a reasonable hypothesis, or unsuccessful claims because required factors, timeframes or service relationships are not established.

Compliance with the Statement of Principles requires assembling and presenting the kind of medical, service and exposure evidence that the SoP specifies. The instrument is an evidentiary standard: at least one s 9 factor must be established and related to relevant service (s 10(1)). The following practical compliance steps are grounded in the instrument’s terms and the Schedule.

1. Identify the statutory claim hook. Confirm that the claimant’s claim is one "to which section 120A of the VEA or section 338 of the MRCA applies" (s 5). The SoP applies only where those statutory provisions are in play. If in doubt, verify the statutory basis under which the claim will be advanced.

2. Determine whether the condition fits the SoP’s definition. Use s 7(2) and Schedule definitions to confirm the claimant’s condition is within the instrument’s working definition of hypothyroidism (clinical symptoms or need for treatment, and primary/central/peripheral forms). If the claimant’s presentation is Hashimoto thyroiditis or an excluded diagnosis (s 7(2)(c)), follow s 11 to identify and apply the correct SoP.

3. Establish onset and/or worsening dates precisely. The instrument distinguishes clinical onset from clinical worsening (ss 9(1)-(21) and 9(22)-(44)). Record the date of diagnosis, first clinical symptoms, and date(s) of any clinical worsening. For myxoedema coma, use the Schedule’s specific definition to determine whether that presentation applies.

4. Map relevant factors to evidence. For each s 9 factor that may apply, collect the specific documentary evidence required by the factor and Schedule thresholds:

• Iodine deficiency/excess (ss 9(1)-(2), 9(22)-(23)): obtain urinary iodine concentration tests and dietary history. The Schedule defines deficiency as average intake <150 µg/day (<250 µg/day for pregnant/lactating) for ≥30 continuous days or urinary iodine <100 µg/L (<150 µg/L for pregnant women). Excess is >1,100 µg/day for adults (>900 µg/day for ≤18 years) for ≥3 months or urinary iodine >300 µg/L (>500 µg/L for pregnant women).

• Iodine‑containing radiographic contrast (ss 9(3), 9(24)): document contrast administration dates and the dosage if possible; show administration occurred within six months before onset/worsening.

• Specified list of drugs (ss 9(4), 9(25)): obtain medication charts, prescription records, pharmacy dispensing records and hospital records showing the drug name, dose, start and end dates; compare to the Schedule’s specified list (Schedule 1) for exact naming.

• Minocycline (ss 9(5), 9(26)): establish continuous minocycline use for at least six months within the nine‑month look‑back window; obtain dispensing records.

• Drugs containing ≥10 mg iodine (ss 9(6), 9(27)): document the drug product and quantify iodine content if necessary, and show continuous use for at least four weeks within the six months before onset/worsening.

• Amiodarone (ss 9(7), 9(28)): document continuous use for at least two weeks within the previous year.

• Pregnancy/postpartum (ss 9(8), 9(30)): obtain obstetric records to show pregnancy status or postpartum timing relative to onset/worsening (postpartum defined within 12 months).

• Forms of thyroiditis (ss 9(9), 9(31)): establish the presence of a specified form of thyroiditis at the time of onset/worsening using pathology, imaging or specialist notes; compare to the specified list in Schedule 1.

• Therapeutic radiation and radioactive iodine (ss 9(10)-(11), 9(32)-(33)): obtain oncology and radiotherapy records showing the field included the thyroid or document receipt of iodine‑131.

• Thyroidectomy/neck surgery (ss 9(12), 9(34)): obtain operation notes and pathology reports.

• Specified diseases (ss 9(13), 9(35)): supply contemporaneous diagnosis/treatment records for any of the listed diseases in the Schedule.

• Malignant neoplasm/type 3 deiodinase overexpressing neoplasm (ss 9(14)-(15), 9(36)-(37)): obtain oncologic pathology and molecular reports where available.

• Hypopituitarism (ss 9(16), 9(38)): provide endocrinology notes and hormone testing showing TSH deficiency.

• Chronic kidney disease (ss 9(17), 9(39)): use GFR values (<60 mL/min/1.73 m2 for ≥3 months) or albuminuria ≥3 mg/mmol for ≥3 months or other markers listed in Schedule 1.

• Hepatitis C infection (ss 9(18), 9(40)): supply serology and records.

• Obesity for ≥5 years (ss 9(19), 9(41)): assemble serial weight and height records sufficient to show BMI ≥30 over the five‑year period. Use the Schedule’s BMI formula.

• PTSD (ss 9(20), 9(42)): obtain formal psychiatric diagnosis and records showing timing relative to onset/worsening.

• Acute precipitating events and myxoedema coma (ss 9(21), 9(43), Schedule 1): collect hospital notes, ICU records, documentation of precipitating events listed in Schedule 1 (e.g. abrupt cessation of thyroxine, infection, surgery).

• Drugs increasing thyroid hormone requirement (s 9(29)): document the drug and timing; where the Schedule lists examples, provide evidence of use.

• Inability to obtain appropriate management (s 9(44)): document attempts to access care, referral records, communications, rationing or service limitations and clinical consequences.

5. Link the factor to relevant service. For any factor relied on, produce service records, deployment logs, medical centre records during service, or administrative records that evidence the link between the factor and the person's relevant service (s 10(1)). For aggravation claims invoking ss 9(22)-(44), ensure the hypothyroidism pre‑existed or was contracted before/during service and did not arise out of service (s 10(2)). This will often require a pre‑service or early service medical record showing pre‑existing hypothyroidism and then evidence that service materially contributed to its worsening.

6. Cross‑check other SoPs. If any factor points to a disease covered by another SoP (s 11), obtain and follow the factors and evidence requirements from that other SoP "as in force from time to time". Do not assume this SoP’s factors will cover that overlap.

7. Use specialist medical evidence. Given the medical specificity (e.g. biochemical thresholds, drug pharmacology, radiation fields), obtain treating specialist opinions (endocrinologists, oncologists, nephrologists, psychiatrists) that explicitly state whether the clinical evidence meets the SoP’s definitions and which s 9 factor(s) are present, and whether they are related to the person's relevant service.

8. Address excluded conditions expressly. If a claimant’s diagnosis is in the exclusion list (s 7(2)(c)), document why the presentation nonetheless falls within this SoP’s definition or, if it does not, identify the relevant alternate SoP.

9. Prepare for contested interpretations. Anticipate areas that tribunals may scrutinise: exact timing (continuous periods), laboratory thresholds (single vs serial measurements), and the meaning of phrases such as "related to the relevant service" or "inability to obtain appropriate clinical management." Provide contemporaneous documentary evidence where possible.

10. Record and preserve evidence for numeric thresholds. For urinary iodine concentration, GFR, albuminuria, BMI, medication dosing and duration, preserve original laboratory reports, pharmacy records and primary clinical documents rather than summaries.

11. Review repeal implications. Because the 2013 SoP is repealed (s 4), evaluate whether pre‑commencement evidence relied upon the prior instrument. If so, update or obtain additional evidence to satisfy the 2022 instrument’s factors.

12. Keep contemporaneous service documentation. Service medical records, deployment details and any in‑service exposures (contrast studies, iodine treatments, therapeutic radiation, drug administration) are critical to satisfying both the factor existence and the relationship to relevant service requirement.

Following these steps will align documentary and medical evidence with the instrument’s factors and definitions and will assist decision‑makers when applying this SoP to claims under the VEA and MRCA.